GMAB - Genmab A/S Debt to Book Capitalization Ratio

Strict FDA oversight and patent protection for bispecific antibodies create significant barriers to entry for competitors. Analyzing the monitoring of the company's debt-to-equity ratio on GURU.Markets, we note that 0.83 shows the level of this metric. A stable staff of R&D specialists and the impeccable reputation of Genmab A/S (GMAB) in global oncology guarantee leadership in the field of precision cancer therapy.

GMAB Genmab A/S: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/27/2026

Summary analytical data breakdowns for Genmab AS (GMAB)

- price and consensus price forecast:

Stock Price Genmab A/S|GMAB - Consensus Target

- market capitalization data:

Market Value Genmab Corp|GMAB - Total Enterprise Value

- book capitalization data:

Net Assets per Single Share Genmab|GMAB - Company Book Value|Market Value to Book Value Ratio genmab.com|GMAB - Company Assets

- debt and liquidity data:

Total Debt to Capital Genmab A/S|GMAB - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Genmab US|GMAB - Company Cumulative Debt|Debt to Book Value Genmab Corp

Analysis of all company metrics:GMAB, Genmab A/S

This metric compares total liabilities to the book value of equity, allowing for a real-time assessment of debt load dynamics and asset devaluation risks. The stability of this capital structure risk indicator on the balance sheet confirms the financial resilience of Genmab A/S, which correlates with the flawless organization of high-tech logistics during the transportation of monoclonal antibodies to medical centers.

Competitors of Genmab A/S (GMAB)